GLP-1 Weight Loss Drugs Tied to Hair Loss, Sparking New Treatment Market
As GLP-1 drugs like Ozempic and Mounjaro become increasingly popular, many users are experiencing significant hair loss as a side effect, leading to a booming market for specialized hair care treatments designed to prevent or counteract thinning.
The Hair Loss Epidemic Among GLP-1 Users
Growing Side Effect Concern: Users of popular weight loss medications including Mounjaro and Zepbound are reporting substantial hair loss, with the effect becoming pronounced about a year into treatment. The drugs list hair loss as a known side effect, but many patients weren't prepared for its severity.
Market Response: Hair care companies including Redken, Nutrafol, and KeraFactor are capitalizing on the trend, reporting 100% year-over-year growth in some cases. Redken specifically developed a product line tested on GLP-1 users, while Nutrafol expects continued growth as more people adopt these medications.
Projected Growth: According to JPMorgan estimates, roughly 25 million Americans will be taking GLP-1 drugs by 2030, up from 5 million in 2023—meaning the hair loss issue could affect millions of patients.
Coping Strategies: Users are trying preventative approaches including increased protein intake, specialized vitamins, and hair growth products. However, the cosmetic impact remains a significant concern even for those successfully losing weight.